1. Home
  2. ESPR vs TCI Comparison

ESPR vs TCI Comparison

Compare ESPR & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESPR
  • TCI
  • Stock Information
  • Founded
  • ESPR 2008
  • TCI 1983
  • Country
  • ESPR United States
  • TCI United States
  • Employees
  • ESPR N/A
  • TCI N/A
  • Industry
  • ESPR Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • ESPR Health Care
  • TCI Finance
  • Exchange
  • ESPR Nasdaq
  • TCI Nasdaq
  • Market Cap
  • ESPR 208.1M
  • TCI 239.1M
  • IPO Year
  • ESPR 2013
  • TCI N/A
  • Fundamental
  • Price
  • ESPR $1.07
  • TCI $42.35
  • Analyst Decision
  • ESPR Buy
  • TCI
  • Analyst Count
  • ESPR 7
  • TCI 0
  • Target Price
  • ESPR $5.93
  • TCI N/A
  • AVG Volume (30 Days)
  • ESPR 4.1M
  • TCI 2.8K
  • Earning Date
  • ESPR 08-11-2025
  • TCI 08-07-2025
  • Dividend Yield
  • ESPR N/A
  • TCI N/A
  • EPS Growth
  • ESPR N/A
  • TCI 59.61
  • EPS
  • ESPR N/A
  • TCI 0.92
  • Revenue
  • ESPR $259,574,000.00
  • TCI $47,452,000.00
  • Revenue This Year
  • ESPR $4.07
  • TCI N/A
  • Revenue Next Year
  • ESPR N/A
  • TCI N/A
  • P/E Ratio
  • ESPR N/A
  • TCI $44.17
  • Revenue Growth
  • ESPR 12.99
  • TCI N/A
  • 52 Week Low
  • ESPR $0.69
  • TCI $25.50
  • 52 Week High
  • ESPR $3.94
  • TCI $41.29
  • Technical
  • Relative Strength Index (RSI)
  • ESPR 51.40
  • TCI 70.15
  • Support Level
  • ESPR $1.13
  • TCI $38.35
  • Resistance Level
  • ESPR $1.22
  • TCI $40.49
  • Average True Range (ATR)
  • ESPR 0.08
  • TCI 1.27
  • MACD
  • ESPR 0.00
  • TCI 0.15
  • Stochastic Oscillator
  • ESPR 52.38
  • TCI 100.00

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: